RecruitingPhase 2NCT04698252

Local Therapy for ER/PR-positive Oligometastatic Breast Cancer

Local Therapy for Hormone Receptor-positive Oligometastatic Breast Cancer - a Phase II Randomized Trial

Sponsor

Instituto do Cancer do Estado de São Paulo

Enrollment

74 participants

Start Date

Apr 1, 2021

Study Type

INTERVENTIONAL

Conditions

Breast Cancer

Summary

Randomized phase 2 trial to evaluate the efficacy of local therapy for oligometastasis from ER/PR-positive breast cancer. The study hypothesis is that local therapy in addition to systemic therapy improves progression-free survival in comparison with systemic therapy alone.

Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria12

Female sex
≥ 18 years of age
Histologically confirmed invasive breast cancer, with oligometastatic disease defined as one of the following criteria: 1) One to four bone lesions; 2) One to four lung and/ or hepatic lesions; 3) Distant metastasis limited to ipsilateral cervical lymph nodes; 4) Distant metastasis limited to contralateral axillary lymph nodes
Oligometastatic sites amenable to treatment with a local therapy modality, including surgical resection, stereotactic radiotherapy, or radiofrequency ablation
Estrogen receptor-positive and/ or progesterone receptor-positive breast cancer
Partial response or stable disease after at least six months of systemic therapy for breast cancer
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Measurable or non-measuble disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Life expectancy of at least 12 weeks
For women in childbearing age, negative pregnancy test until 21 days before the date of study enrollment.
Signed informed consent form
Disposition and aptitude to fulfill the study protocol during the study duration

Exclusion Criteria5

HER2-positive breast cancer
Progressive disease during the last systemic treatment received for metastatic disease
Previous local therapy for distant metastasis
Current or previous history of severe diseases, such as clinically relevant heart failure, acute myocardium infarction in the last six months, chronic obstructive lung disease, HIV infection, chronic active hepatitis B or C infection, current serious uncontrolled infections or other severe diseases that may impact patients' expected survival)
Current or previous history of other invasive malignancy within the last five years, excluding non-melanoma skin cancer